Characterization of AQX-1125, a small-molecule SHIP1 activator Part 2. Efficacy studies in allergic and pulmonary inflammation models in vivo

Grant R. Stenton, Lloyd F. MacKenzie, Patrick Tam, Jennifer L. Cross, Curtis Harwig, Jeffrey Raymond, Judy Toews, David Chernoff, Thomas MacRury, Csaba Szabo

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

Background The efficacy of AQX-1125, a small-molecule SH2-containing inositol-5′-phosphatase 1 (SHIP1) activator and clinical development candidate, is investigated in rodent models of inflammation. Experimental Approach AQX-1125 was administered orally in a mouse model of passive cutaneous anaphylaxis (PCA) and a number of rodent models of respiratory inflammation including: cigarette smoke, LPS and ovalbumin (OVA)-mediated airway inflammation. SHIP1 dependency of the AQX-1125 mechanism of action was investigated by comparing the efficacy in wild-type and SHIP1-deficient mice subjected to an intrapulmonary LPS challenge. Results AQX-1125 exerted anti-inflammatory effects in all of the models studied. AQX-1125 decreased the PCA response at all doses tested. Using bronchoalveolar lavage (BAL) cell counts as an end point, oral or aerosolized AQX-1125 dose dependently decreased the LPS-mediated pulmonary neutrophilic infiltration at 3-30 mg kg-1 and 0.15-15 μg kg-1 respectively. AQX-1125 suppressed the OVA-mediated airway inflammation at 0.1-10 mg kg-1. In the smoke-induced airway inflammation model, AQX-1125 was tested at 30 mg kg-1 and significantly reduced the neutrophil infiltration of the BAL fluid. AQX-1125 (10 mg kg-1) decreased LPS-induced pulmonary neutrophilia in wild-type mice but not in SHIP1-deficient mice. Conclusions The SHIP1 activator, AQX-1125, suppresses leukocyte accumulation and inflammatory mediator release in rodent models of pulmonary inflammation and allergy. As shown in the mouse model of LPS-induced lung inflammation, the efficacy of the compound is dependent on the presence of SHIP1. Pharmacological SHIP1 activation may have clinical potential for the treatment of pulmonary inflammatory diseases. Linked Article This article is accompanied by Stenton et al., pp. 1506-1518 of this issue. To view this article visit http://dx.doi.org/10.1111/bph.12039

Original languageEnglish (US)
Pages (from-to)1519-1529
Number of pages11
JournalBritish Journal of Pharmacology
Volume168
Issue number6
DOIs
StatePublished - Mar 2013
Externally publishedYes

Fingerprint

Pneumonia
Inflammation
Rodentia
Passive Cutaneous Anaphylaxis
Ovalbumin
Smoke
Inositol Polyphosphate 5-Phosphatases
4-(4-(aminomethyl)-7a-methyl-1-methylideneoctahydro-1H-inden-5-yl)-3-(hydroxymethyl)-4-methylcyclohexan-1-ol
Lung
Neutrophil Infiltration
Bronchoalveolar Lavage Fluid
Bronchoalveolar Lavage
Tobacco Products
Lung Diseases
Hypersensitivity
Leukocytes
Anti-Inflammatory Agents
Cell Count
Pharmacology

Keywords

  • asthma
  • chemotaxis
  • COPD
  • inflammation
  • PI3K
  • pulmonary
  • SHIP1

ASJC Scopus subject areas

  • Pharmacology

Cite this

Characterization of AQX-1125, a small-molecule SHIP1 activator Part 2. Efficacy studies in allergic and pulmonary inflammation models in vivo. / Stenton, Grant R.; MacKenzie, Lloyd F.; Tam, Patrick; Cross, Jennifer L.; Harwig, Curtis; Raymond, Jeffrey; Toews, Judy; Chernoff, David; MacRury, Thomas; Szabo, Csaba.

In: British Journal of Pharmacology, Vol. 168, No. 6, 03.2013, p. 1519-1529.

Research output: Contribution to journalArticle

Stenton, GR, MacKenzie, LF, Tam, P, Cross, JL, Harwig, C, Raymond, J, Toews, J, Chernoff, D, MacRury, T & Szabo, C 2013, 'Characterization of AQX-1125, a small-molecule SHIP1 activator Part 2. Efficacy studies in allergic and pulmonary inflammation models in vivo', British Journal of Pharmacology, vol. 168, no. 6, pp. 1519-1529. https://doi.org/10.1111/bph.12038
Stenton, Grant R. ; MacKenzie, Lloyd F. ; Tam, Patrick ; Cross, Jennifer L. ; Harwig, Curtis ; Raymond, Jeffrey ; Toews, Judy ; Chernoff, David ; MacRury, Thomas ; Szabo, Csaba. / Characterization of AQX-1125, a small-molecule SHIP1 activator Part 2. Efficacy studies in allergic and pulmonary inflammation models in vivo. In: British Journal of Pharmacology. 2013 ; Vol. 168, No. 6. pp. 1519-1529.
@article{39a5e89e39734bc6999c2f6b594c4c30,
title = "Characterization of AQX-1125, a small-molecule SHIP1 activator Part 2. Efficacy studies in allergic and pulmonary inflammation models in vivo",
abstract = "Background The efficacy of AQX-1125, a small-molecule SH2-containing inositol-5′-phosphatase 1 (SHIP1) activator and clinical development candidate, is investigated in rodent models of inflammation. Experimental Approach AQX-1125 was administered orally in a mouse model of passive cutaneous anaphylaxis (PCA) and a number of rodent models of respiratory inflammation including: cigarette smoke, LPS and ovalbumin (OVA)-mediated airway inflammation. SHIP1 dependency of the AQX-1125 mechanism of action was investigated by comparing the efficacy in wild-type and SHIP1-deficient mice subjected to an intrapulmonary LPS challenge. Results AQX-1125 exerted anti-inflammatory effects in all of the models studied. AQX-1125 decreased the PCA response at all doses tested. Using bronchoalveolar lavage (BAL) cell counts as an end point, oral or aerosolized AQX-1125 dose dependently decreased the LPS-mediated pulmonary neutrophilic infiltration at 3-30 mg kg-1 and 0.15-15 μg kg-1 respectively. AQX-1125 suppressed the OVA-mediated airway inflammation at 0.1-10 mg kg-1. In the smoke-induced airway inflammation model, AQX-1125 was tested at 30 mg kg-1 and significantly reduced the neutrophil infiltration of the BAL fluid. AQX-1125 (10 mg kg-1) decreased LPS-induced pulmonary neutrophilia in wild-type mice but not in SHIP1-deficient mice. Conclusions The SHIP1 activator, AQX-1125, suppresses leukocyte accumulation and inflammatory mediator release in rodent models of pulmonary inflammation and allergy. As shown in the mouse model of LPS-induced lung inflammation, the efficacy of the compound is dependent on the presence of SHIP1. Pharmacological SHIP1 activation may have clinical potential for the treatment of pulmonary inflammatory diseases. Linked Article This article is accompanied by Stenton et al., pp. 1506-1518 of this issue. To view this article visit http://dx.doi.org/10.1111/bph.12039",
keywords = "asthma, chemotaxis, COPD, inflammation, PI3K, pulmonary, SHIP1",
author = "Stenton, {Grant R.} and MacKenzie, {Lloyd F.} and Patrick Tam and Cross, {Jennifer L.} and Curtis Harwig and Jeffrey Raymond and Judy Toews and David Chernoff and Thomas MacRury and Csaba Szabo",
year = "2013",
month = "3",
doi = "10.1111/bph.12038",
language = "English (US)",
volume = "168",
pages = "1519--1529",
journal = "British Journal of Pharmacology",
issn = "0007-1188",
publisher = "Wiley-Blackwell",
number = "6",

}

TY - JOUR

T1 - Characterization of AQX-1125, a small-molecule SHIP1 activator Part 2. Efficacy studies in allergic and pulmonary inflammation models in vivo

AU - Stenton, Grant R.

AU - MacKenzie, Lloyd F.

AU - Tam, Patrick

AU - Cross, Jennifer L.

AU - Harwig, Curtis

AU - Raymond, Jeffrey

AU - Toews, Judy

AU - Chernoff, David

AU - MacRury, Thomas

AU - Szabo, Csaba

PY - 2013/3

Y1 - 2013/3

N2 - Background The efficacy of AQX-1125, a small-molecule SH2-containing inositol-5′-phosphatase 1 (SHIP1) activator and clinical development candidate, is investigated in rodent models of inflammation. Experimental Approach AQX-1125 was administered orally in a mouse model of passive cutaneous anaphylaxis (PCA) and a number of rodent models of respiratory inflammation including: cigarette smoke, LPS and ovalbumin (OVA)-mediated airway inflammation. SHIP1 dependency of the AQX-1125 mechanism of action was investigated by comparing the efficacy in wild-type and SHIP1-deficient mice subjected to an intrapulmonary LPS challenge. Results AQX-1125 exerted anti-inflammatory effects in all of the models studied. AQX-1125 decreased the PCA response at all doses tested. Using bronchoalveolar lavage (BAL) cell counts as an end point, oral or aerosolized AQX-1125 dose dependently decreased the LPS-mediated pulmonary neutrophilic infiltration at 3-30 mg kg-1 and 0.15-15 μg kg-1 respectively. AQX-1125 suppressed the OVA-mediated airway inflammation at 0.1-10 mg kg-1. In the smoke-induced airway inflammation model, AQX-1125 was tested at 30 mg kg-1 and significantly reduced the neutrophil infiltration of the BAL fluid. AQX-1125 (10 mg kg-1) decreased LPS-induced pulmonary neutrophilia in wild-type mice but not in SHIP1-deficient mice. Conclusions The SHIP1 activator, AQX-1125, suppresses leukocyte accumulation and inflammatory mediator release in rodent models of pulmonary inflammation and allergy. As shown in the mouse model of LPS-induced lung inflammation, the efficacy of the compound is dependent on the presence of SHIP1. Pharmacological SHIP1 activation may have clinical potential for the treatment of pulmonary inflammatory diseases. Linked Article This article is accompanied by Stenton et al., pp. 1506-1518 of this issue. To view this article visit http://dx.doi.org/10.1111/bph.12039

AB - Background The efficacy of AQX-1125, a small-molecule SH2-containing inositol-5′-phosphatase 1 (SHIP1) activator and clinical development candidate, is investigated in rodent models of inflammation. Experimental Approach AQX-1125 was administered orally in a mouse model of passive cutaneous anaphylaxis (PCA) and a number of rodent models of respiratory inflammation including: cigarette smoke, LPS and ovalbumin (OVA)-mediated airway inflammation. SHIP1 dependency of the AQX-1125 mechanism of action was investigated by comparing the efficacy in wild-type and SHIP1-deficient mice subjected to an intrapulmonary LPS challenge. Results AQX-1125 exerted anti-inflammatory effects in all of the models studied. AQX-1125 decreased the PCA response at all doses tested. Using bronchoalveolar lavage (BAL) cell counts as an end point, oral or aerosolized AQX-1125 dose dependently decreased the LPS-mediated pulmonary neutrophilic infiltration at 3-30 mg kg-1 and 0.15-15 μg kg-1 respectively. AQX-1125 suppressed the OVA-mediated airway inflammation at 0.1-10 mg kg-1. In the smoke-induced airway inflammation model, AQX-1125 was tested at 30 mg kg-1 and significantly reduced the neutrophil infiltration of the BAL fluid. AQX-1125 (10 mg kg-1) decreased LPS-induced pulmonary neutrophilia in wild-type mice but not in SHIP1-deficient mice. Conclusions The SHIP1 activator, AQX-1125, suppresses leukocyte accumulation and inflammatory mediator release in rodent models of pulmonary inflammation and allergy. As shown in the mouse model of LPS-induced lung inflammation, the efficacy of the compound is dependent on the presence of SHIP1. Pharmacological SHIP1 activation may have clinical potential for the treatment of pulmonary inflammatory diseases. Linked Article This article is accompanied by Stenton et al., pp. 1506-1518 of this issue. To view this article visit http://dx.doi.org/10.1111/bph.12039

KW - asthma

KW - chemotaxis

KW - COPD

KW - inflammation

KW - PI3K

KW - pulmonary

KW - SHIP1

UR - http://www.scopus.com/inward/record.url?scp=84874449540&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84874449540&partnerID=8YFLogxK

U2 - 10.1111/bph.12038

DO - 10.1111/bph.12038

M3 - Article

VL - 168

SP - 1519

EP - 1529

JO - British Journal of Pharmacology

JF - British Journal of Pharmacology

SN - 0007-1188

IS - 6

ER -